Actuate Therapeutics, Inc. Increase (Decrease) in Other Accrued Liabilities
Actuate Therapeutics, Inc. (ACTU) reported Increase (Decrease) in Other Accrued Liabilities of -$1.26 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccruedLiabilities · last filed 2026-08-14
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-06-30 was -$297.99K.
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2026-03-31 was -$964.79K.
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-12-31 was -$691.64K.
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for the quarter ending 2025-09-30 was -$311.58K, a 420.38% decline year-over-year.
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2025 was -$2.35M, a 187.18% decline from fiscal 2024.
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2024 was $2.70M, a 137.08% increase from fiscal 2023.
- Actuate Therapeutics, Inc. increase (decrease) in other accrued liabilities for fiscal 2023 was $1.14M.
| Period end | Increase (Decrease) in Other Accrued Liabilities 3 month | Increase (Decrease) in Other Accrued Liabilities 6 month | Increase (Decrease) in Other Accrued Liabilities 9 month | Increase (Decrease) in Other Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$297.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.26M 10-Q · filed 2026-08-14 | -$1.95M derived: sum of 3 quarters · filed 2026-08-14 | -$2.27M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$964.79K 10-Q · filed 2026-05-14 | -$1.66M derived: sum of 2 quarters · filed 2026-05-14 | -$1.97M derived: sum of 3 quarters · filed 2026-05-14 | -$2.60M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$691.64K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$1.00M derived: sum of 2 quarters · filed 2026-03-26 | -$1.63M derived: sum of 3 quarters · filed 2026-08-14 | -$2.35M 10-K · filed 2026-03-26 |
| 2025-09-30 | -$311.58K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$941.71K derived: sum of 2 quarters · filed 2026-08-14 | -$1.66M 10-Q · filed 2025-11-13 | -$1.83M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$630.13K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$1.35M 10-Q · filed 2026-08-14 | -$1.52M derived: sum of 3 quarters · filed 2026-08-14 | -$1.43M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$721.15K 10-Q · filed 2026-05-14 | -$892.19K derived: sum of 2 quarters · filed 2026-05-14 | -$794.93K derived: sum of 3 quarters · filed 2026-05-14 | $17.66K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$171.04K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | -$73.79K derived: sum of 2 quarters · filed 2026-03-26 | $738.81K derived: sum of 3 quarters · filed 2026-03-26 | $2.70M 10-K · filed 2026-03-26 |
| 2024-09-30 | $97.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $909.85K derived: sum of 2 quarters · filed 2025-11-13 | $2.87M 10-Q · filed 2025-11-13 | $3.66M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $812.60K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $2.77M 10-Q · filed 2025-08-14 | $3.56M derived: sum of 3 quarters · filed 2025-08-14 | $3.90M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $1.96M 10-Q · filed 2025-05-15 | $2.75M derived: sum of 2 quarters · filed 2025-05-15 | $3.09M derived: sum of 3 quarters · filed 2025-05-15 | |
| 2023-12-31 | $786.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $1.12M derived: sum of 2 quarters · filed 2025-03-13 | $1.14M 10-K · filed 2025-03-13 | |
| 2023-09-30 | $338.20K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | $352.77K 10-Q · filed 2024-11-13 | ||
| 2023-06-30 | $14.57K 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |